Bevacizumab-awwb - Biologic Drug Details

Summary for bevacizumab-awwb

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for bevacizumab-awwb

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for bevacizumab-awwb Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for bevacizumab-awwb Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for bevacizumab-awwb Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory of Bevacizumab-awwb (Zirabev)

Last updated: February 13, 2026

Overview

Bevacizumab-awwb (brand: Zirabev) is a biosimilar to Roche’s Avastin (bevacizumab). It received FDA approval in May 2019 for several cancer indications, including metastatic colorectal cancer, non-small cell lung cancer, and glioblastoma. As a biosimilar, Zirabev aims to provide a cost-effective alternative to Avastin while maintaining similar efficacy, safety, and immunogenicity profiles.

Market Penetration and Competition

• Initial Launch and Adoption: Zirabev entered the U.S. oncology market when biosimilars were gaining acceptance. The drug initially gained market share through strategic pricing and partnerships with major healthcare providers.

• Pricing Strategy: Zirabev is priced approximately 15-20% lower than originator Avastin, in line with biosimilar pricing trends. According to IQVIA data (2022), biosimilars typically achieve a 30-50% discount relative to originator biologics within their first three years on the market.

• Competition: Zirabev faces direct competition from other bevacizumab biosimilars approved in the U.S., including Amgen’s mvasi and Pfizer’s bevacizumab-bii. The competition has driven price reductions and increased market share for biosimilars overall.

• Market Share Trends: By the end of 2022, Zirabev captured an estimated 10-15% of the global bevacizumab market, primarily in the U.S. and Europe. Its U.S. market share is estimated to be around 7-12%, with steady growth observed through 2022 and 2023.

Market Size and Forecast

• Global Oncology Market: The total biologic oncology market was valued at approximately $120 billion in 2022, with bevacizumab accounting for nearly $6 billion of sales worldwide.

• U.S. Market: The U.S. accounts for roughly 60% of Avastin’s sales. In 2022, U.S. Avastin sales were approximately $3.6 billion, indicating a sizable market for biosimilar penetration.

• Projected Growth: According to Evaluate Pharma, biosimilars in oncology are projected to grow at a CAGR of 20% through 2027, driven by patent expirations and cost containment efforts. Zirabev is expected to benefit from this trend, with further market penetration anticipated as physicians and payers become more comfortable with biosimilars.

Financial Trajectory

• Revenue Estimates: Zirabev’s revenues reached approximately $350 million globally in 2022, with the majority derived from the U.S. It is projected to grow at a CAGR of 15-20% over the next five years, reaching over $800 million by 2027.

• Pricing Dynamics: A key driver of revenue growth will be increased volume rather than price hikes. Biosimilar price erosion has stabilized at around 20-25%, with some variations based on payor negotiations and institutional policies.

• Cost and Margins: Manufacturing costs for Zirabev are comparable to other biosimilars, with gross margins estimated at 60-65%. R&D and marketing expenses maintain a moderate level to support market expansion.

Regulatory and Policy Impact

• Patent Expiry & Market Entry: Patent litigation delays have historically slowed biosimilar entry. For Avastin, key patents expired around 2018-2019 in the U.S., enabling biosimilar development and approval.

• Reimbursement Policies: The Centers for Medicare & Medicaid Services (CMS) promotes biosimilar adoption through reimbursement policies favoring biosimilars over originators, encouraging more prescribing of Zirabev.

• Global Regulatory Environment: European Medicines Agency (EMA) approved Zirabev in 2020, with broader uptake across European countries, providing additional growth pathways.

Risks and Opportunities

• Risks: Price erosion, physician inertia, slow adoption, and potential legal challenges pose risks to Zirabev’s market share and revenue growth.

• Opportunities: Expanding indications, such as combination therapies or new oncology settings, and emerging markets, particularly in Asia, can boost future sales.

---

Key Takeaways

• Zirabev is a leading biosimilar to Avastin, targeting a lucrative oncology market with steady growth prospects.
• Its market share remains modest but expanding, driven by competitive pricing and increasing biosimilar acceptance.
• Revenue is projected to grow at approximately 15-20% annually through 2027, reaching over $800 million.
• Competitive pressures and policy shifts will influence pricing, margins, and adoption rates.
• Opportunities exist in expanding indications and emerging markets; risks include legal challenges and slower uptake.

FAQs

1. What is the main driver for Zirabev’s market growth?
Market growth primarily depends on increased biosimilar acceptance, physician preference for cost-effective options, and expanding indications.

2. How does Zirabev compare to other bevacizumab biosimilars?
It generally offers comparable efficacy and safety with a slightly lower price point but faces stiff competition from mvasi and bevacizumab-bii, which also hold significant market shares.

3. What factors could limit Zirabev’s growth?
Legal challenges to patent rights, slow physician adoption, payer resistance, and aggressive pricing strategies by competitors could limit growth.

4. What is the outlook for biosimilars in oncology?
Biosimilars are expected to account for up to 50% of biologic oncology sales by 2027, driven by patent expirations and initiatives to contain healthcare costs.

5. How does regulatory environment influence Zirabev's potential?
Approval in key markets like Europe and supportive reimbursement policies in the U.S. will be instrumental in expanding Zirabev’s sales.

---

Sources

[1] IQVIA, "Biosimilar Market Data," 2022
[2] Evaluate Pharma, "Biologics & Biosimilars Forecast," 2022-2027
[3] U.S. Food & Drug Administration, "FDA Approvals," 2019
[4] European Medicines Agency, "Zirabev Approval," 2020
[5] Centers for Medicare & Medicaid Services, "Biosimilar Reimbursement Policies," 2022